A randomized phase II study of degarelix combined with anti-androgen for prostate cancer
Not Applicable
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000011506
- Lead Sponsor
- South-Kinki Prostate Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
Previous or present endocrine therapy for prostate cancer.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in serum level of prostate specific antigen at Day 28.
- Secondary Outcome Measures
Name Time Method